Alphatec (ATEC) Stock Price, News & Analysis

Company Overview

Alphatec Holdings, Inc. (NASDAQ: ATEC) is a medical technology company focused on the surgical treatment of spinal disorders. Through its Alphatec Spine business, the company develops and markets implants, biologics, instruments and procedural technologies designed to support spine surgery and improve patient outcomes.

Its product portfolio includes systems for spinal fusion and reconstruction, including interbody implants, fixation devices and navigation or imaging-enabled surgical solutions. Alphatec also offers technologies intended to assist surgeons with spinal alignment, intraoperative decision-making and neuromonitoring during procedures.

Headquartered in Carlsbad, California, Alphatec serves spine surgeons, hospitals and other healthcare providers in the United States and selected international markets. The company has expanded its capabilities through internal product development and acquisitions, including the addition of SafeOp Surgical, a developer of technology for nerve monitoring during spine procedures. Pat Miles serves as Alphatec’s chairman and chief executive officer.

Key Stats

• Today's Range: $9.94 to $10.75
• 50-Day Range: $8.67 to $10.86
• 52-Week Range: $6.82 to $23.29
• Volume: 2.06 million shs
• Average Volume: 2.92 million shs
• Market Capitalization: $1.66 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.40
• Consensus Rating: Moderate Buy

Alphatec Stock Analysis - MarketRank™

Alphatec scored higher than 74% of companies evaluated by MarketBeat, and ranked 158th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Alphatec has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Alphatec has a consensus price target of $17.40, representing about 65.7% upside from its current price of $10.50.

Amount of Analyst Coverage

Alphatec has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alphatec are expected to grow in the coming year, from ($0.45) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alphatec is -14.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alphatec is -14.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alphatec has a P/B Ratio of 131.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.80% of the float of Alphatec has been sold short.

Short Interest Ratio / Days to Cover

Alphatec has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Alphatec has recently increased by 5.54%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alphatec does not currently pay a dividend.

Dividend Growth

Alphatec does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.52

News Sentiment

Alphatec has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Alphatec this week, compared to 6 articles on an average week.

Search Interest

Only 8 people have searched for ATEC on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

1 people have added Alphatec to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $934,329.00 in company stock, which represents 0.0576% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Alphatec insiders have bought 1,185.38% more of their company's stock than they have sold. Specifically, they have bought $1,013,150.00 in company stock and sold $78,821.00 in company stock.

Percentage Held by Insiders

13.48% of the stock of Alphatec is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.35% of the stock of Alphatec is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ATEC
• CIK: 1350653
• Web: www.atecspine.com
• Phone: (760) 431-9286
• Fax: 800-922-1356
• Employees: 913
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Alphatec: $17.40
• High Price Target: $25.00
• Low Price Target: $12.00
• Potential Upside/Downside: +62.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$143.36 million
• Net Margins: -13.49%
• Pretax Margin: -13.46%
• Return on Equity: -6,752.24%
• Return on Assets: -13.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.89
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $764.16 million
• Price / Sales: 2.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 134.00

Miscellaneous

• Outstanding Shares: 154,450,000
• Free Float: 133,631,000
• Market Cap: $1.66 billion
• Optionable: Optionable
• Beta: 0.78